6 news items
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
ALGS
7 May 24
candidates. In particular, we demonstrated positive safety, tolerability, and antiviral activity data after dosing for up to 64 weeks with our hepatitis B
Aligos Therapeutics Presents Clinical Data At ESCMID 2024 From The ALG-097558 Phase 1 Study
ALGS
25 Apr 24
are as follows:ePoster Flash Session Presentation Title: Safety and pharmacokinetics of single and multiple
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
ALGS
25 Apr 24
are as follows: ePoster Flash Session Presentation Title: Safety and pharmacokinetics
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
ALGS
3 Apr 24
to collecting safety and pharmacokinetic (PK) data, this study will also assess multiple non-invasive biomarkers, which include Magnetic Resonance
Aligos Therapeutics Presents Clinical Data At APASL 2024 From ALG-055009 And ALG-000184 Phase 1 Studies
ALGS
27 Mar 24
-055009 in MASH subjects, we remain encouraged by the data presented showing a favorable safety profile and strong evidence of target engagement, as shown
icihg7xby9c4412edyy4102rqzhmkl8ci07ct6oa00zonv
ALGS
27 Mar 24
in MASH subjects, we remain encouraged by the data presented showing a favorable safety profile and strong evidence of target engagement, as shown
- Prev
- 1
- Next